Sharon Isern from Naples, FL, age 58

Optimized Dengue Virus Entry Inhibitory Peptide (10An)
view source
US Patent:

8637472, Jan 28, 2014
Filed:

Jul 11, 2008
Appl. No.:

12/668808
Inventors:

Scott F. Michael - Estero FL, US
Sharon Isern - Estero FL, US
Joshua Costin - Naples FL, US
Ekachai Jenwitheesuk - Ratchaburi, TH
Assignee:

University of Washington Through Its Center for Commercialization - Seattle WA
Florida Gulf Coast University - Ft. Myers FL
International Classification:

A61K 38/10
A61K 38/00
US Classification:

514 214, 530300
Abstract:

The invention relates peptide entry inhibitors and methods of determining such inhibitors that are bindable to regions of viruses having class II E proteins, such as the dengue virus E protein, as candidates for in vivo anti-viral compounds.

Methods For Delivering Materials Into Biological Systems Using Sonic Energy
view source
US Patent:

20080033296, Feb 7, 2008
Filed:

Feb 15, 2007
Appl. No.:

11/675349
Inventors:

Sharon ISERN - Estero FL, US
Assignee:

FLORIDA GULF COAST UNIVERSITY - Fort Myers FL
International Classification:

A61B 8/00
US Classification:

600439000
Abstract:

Methods to facilitate delivering of materials into biological systems using sonic energy. The processes include a method of controllably disrupting cell membranes and/or cell walls in biological cells using sonic energy, methods of introducing materials into biological cells using sonic energy, and methods of correlating sonic energy exposure to material transport efficiency into biological cells.

Anti-Viral Properties Of Zosteric Acid And Related Molecules
view source
US Patent:

20110100371, May 5, 2011
Filed:

Jul 11, 2008
Appl. No.:

12/668847
Inventors:

Scott F. Michael - Estero FL, US
Sharon Isern - Estero FL, US
Joshua Costin - Naples FL, US
Assignee:

FLORIDA GULF COAST UNIVERSITY - Ft. Myers FL
International Classification:

A62B 7/10
C07C 305/24
C07C 69/732
C07K 14/00
A61K 31/255
A61K 31/216
A61P 31/18
A61P 31/16
A61P 31/14
A01N 41/02
A01N 37/10
A01P 15/00
A01N 25/34
C07K 14/765
B32B 15/04
B32B 9/04
B32B 1/02
US Classification:

12820619, 558 32, 560 75, 530410, 514517, 514532, 424408, 530363, 428457, 4284111, 428 341
Abstract:

The invention relates chemical compound entry inhibitors and methods of determining such inhibitors that interact with regions of viruses, such as the dengue virus, as candidates for in vivo anti-viral compounds.

Optimized Dengue Virus Entry Inhibitory Peptide (Dn81)
view source
US Patent:

20110112031, May 12, 2011
Filed:

Jul 11, 2008
Appl. No.:

12/668828
Inventors:

Scott F. Michael - Estero FL, US
Sharon Isern - Estero FL, US
Robert Garry - New Orleans LA, US
Ram Samudrala - Mukilteo WA, US
Joshua Costin - Naples FL, US
Ekachai Jenwitheesuk - Ratchaburi, TH
Assignee:

FLORIDA GULF COAST UNIVERSITY - Ft. Myers FL
International Classification:

A61K 38/16
C07K 14/00
C12Q 1/70
A61K 38/38
A61P 31/12
US Classification:

514 152, 530324, 514 213, 435 5
Abstract:

The invention relates peptide entry inhibitors and methods of determining such inhibitors that are bindable to regions of viruses having class II E proteins, such as the dengue virus E protein, as candidates for in vivo anti-viral compounds.

Flavivirus-Binding, Entry-Obstructing, Protease-Resistant Peptide (Ri57)
view source
US Patent:

20180155398, Jun 7, 2018
Filed:

Dec 6, 2016
Appl. No.:

15/369893
Inventors:

Scott F. Michael - Estero FL, US
Sharon Isern - Estero FL, US
Assignee:

Ennaid Therapeutics, LLC - Alpharetta GA
International Classification:

C07K 14/00
Abstract:

The invention pertains to inhibitors bindable to regions of a virus. More particularly, the invention relates to inhibitors bindable to regions of flaviviral envelope glycoprotein, or flaviviral virus E protein, a class II viral E protein. Even more particularly, the invention relates to peptides inhibitory to virus-to-cell fusion and virus entry into animal cells. The invention also contains methods of determining said inhibitors, bindable to regions of the flaviviral E protein complex, (e.g., those of dengue and zika viruses) as candidates for in vivo anti-viral compounds that are also resistant to degradation by peptidases and thus extraordinarily suitable for oral, in addition to other, routes of administration.

Vaccines And Methods For Creating A Vaccine For Inducing Immunity To All Dengue Virus Serotypes
view source
US Patent:

20170202945, Jul 20, 2017
Filed:

Jan 23, 2017
Appl. No.:

15/413347
Inventors:

Sharon Isern - Estero FL, US
Scott F. Michael - Estero FL, US
International Classification:

A61K 39/12
C12N 7/00
C07K 14/005
Abstract:

Described here is a method to produce a chimeric protein having portions of yellow fever virus and dengue virus. A small portion of the yellow fever virus 17D vaccine strain envelope protein (or other related ) can be replaced by the corresponding portion from the dengue virus envelope protein. In some embodiments the chimeric protein may be used to create a treatment composition for DENV infection. In others, the chimeric protein may be used to create a vaccine that will induce broadly protective antibodies against dengue virus and reduce the induction of non-neutralizing antibodies that will cause enhancement.